Pamplona Therapeutics and Coherent Biopharma today announced a strategic collaboration to combine Pamplona’s AI-driven targeted protein degradation (TPD) molecular design capabilities with Coherent’s dual-target conjugation technologies, Bi-XDC and C-PROTAC.
Through this partnership, the two companies will jointly explore a new class of degrader–conjugate therapeutics, integrating precision degrader design with advanced targeted delivery technologies. The collaboration aims to expand the therapeutic potential of targeted protein degradation, particularly in chronic diseases and other areas with significant unmet medical needs.
Dr. Baohua Huang, Founder and CEO of Coherent, said:
“We are excited to initiate this collaboration with Pamplona and Dr. Liu’s team. Our Bi-XDC technology platform is designed to address key limitations in drug delivery and conventional antibody-drug conjugates. By combining our delivery capabilities with Pamplona’s AI-driven degrader design, we believe this partnership can unlock new opportunities for innovative therapeutics.”
Dr. Jinsong Liu, CEO of Pamplona Therapeutics, commented:
“Pamplona’s first First-in-Class molecule received FDA clearance for clinical investigation within three years, validating the engineering capability of our ASTRIDE® platform in the TPD field. This collaboration brings together AI-enabled molecular design and next-generation delivery technologies, enabling us to accelerate the development of degrader–conjugate therapeutics and expand the boundaries of targeted protein degradation.”
By integrating AI-powered degrader discovery with precision tissue/cell-targeting Bi-XDC delivery technologies, the collaboration seeks to enhance both the efficacy and targeting capabilities of protein degradation therapeutics. The combined approach aims to enable more effective elimination of disease-driving proteins while improving tissue targeting and pharmacological performance.
About Coherent Biopharma
Coherent is a biotechnology company focused on the development of bispecific-targeting ligand drug conjugates (Bi-XDC). Leveraging its Bi-XDC and C-PROTAC platforms, the company is dedicated to delivering more precise and effective innovative therapies for patients worldwide.
Currently, three First-in-Class Bi-XDC oncology programs have demonstrated promising efficacy and safety profiles in clinical studies. Among them, the first-line prostate cancer therapy CBP-1018 has completed an international licensing transaction valued at up to $2 billion.
About Pamplona Therapeutics
Pamplona is a biotechnology company advancing AI-driven targeted protein degradation (TPD) therapeutics. Its proprietary ASTRIDE® platform integrates AI-based molecular design and structural biology to accelerate the discovery of First-in-Class and Best-in-Class medicines across oncology, autoimmune diseases, and chronic conditions. Pamplona’s first clinical candidate has received FDA IND clearance to initiate clinical trials.